Paradigm Biocapital Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-150,000	Closed	-$2.14M	–	38
2023 Q4	$2.14M	Sell	150,000 -59,600	-28%	-$677K	0.1%	30
2023 Q3	$2.41M	Buy	+209,600	New	+$2.85M	0.16%	30

Paradigm Biocapital Advisors's AMAM Position: Q1 2024 in Review

Paradigm Biocapital Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 4,352,689 shares — an estimated $62M sold.

Paradigm Biocapital Advisors first reported a position in AMAM in Q2 2023 and held it in 3 quarters. The position peaked at $62M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Paradigm Biocapital Advisors reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Paradigm Biocapital Advisors sold 4,352,689 Ambrx Biopharma Inc shares in Q1 2024, an estimated $62M.
Paradigm Biocapital Advisors first reported a position in Ambrx Biopharma Inc in Q2 2023 and held it in 3 quarters.
Paradigm Biocapital Advisors's Ambrx Biopharma Inc position peaked at $62M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.